The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 24, 2024
Filed:
Nov. 02, 2022
Applicant:
Janssen Biotech, Inc., Horsham, PA (US);
Inventors:
Jenna Goldberg, Raritan, NJ (US);
Jagoda Jasielec, Spring House, PA (US);
Raluca Verona, Spring House, PA (US);
Brendan Weiss, Spring House, PA (US);
Assignee:
Janssen Biotech, Inc., Horsham, PA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 31/454 (2006.01); A61K 31/573 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 31/454 (2013.01); A61K 31/573 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01);
Abstract
Disclosed are methods of treating cancers and enhancing efficacy of BCMAxCD3 bispecific antibodies. In particular, methods are disclosed of using a BCMAxCD3 bispecific antibody, an anti-CD38 antibody and/or pomalidomide to treat cancers, particularly relapsed or refractory multiple myeloma.